Bayer Bids To Be A Winner In Cell & Gene Therapy
Adopts Four-Pillar Strategy
The last six weeks have seen the acquisition of AskBio, the launch of a dedicated cell and gene therapy unit and a CAR-T pact with Atara. Bayer is taking the space very seriously.
You may also be interested in...
Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.
Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.